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We have recently shown that human papillomavirus (HPV16) E6 oncoprotein exhibits two separate biological activities in
genital keratinocytes (PHKs). E6 protein by itself is capable of inducing colonies of proliferating cells resistant to serum
and calcium-induced differentiation, whereas both E6 and E7 are required for immortalization of PHK. Using epitope-tagged
E6 carboxy-terminal truncation mutants, we mapped the domain between amino acid residues 132 and 141 as being
essential for the induction of differentiation resistance (L. Sherman and R. Schlegel, J. Virol. 70, 3269–3279, 1996). To
determine whether E6 protein’s ability to alter PHK response to serum and calcium was associated with its ability to
inactivate p53, we evaluated each of the above E6 mutants and three E6 natural variants in these respective assays. Our
results demonstrate that the E6 region spanning residues 132–141 is required for p53 degradation and for abrogation of
p53 transactivation, suggesting a possible correlation between E6 biological activity in altering differentiation and loss of
p53 function. To evaluate whether selective inactivation of p53 is sufficient for altering the response of PHK to serum and
calcium we investigated the capacity of plasmids encoding a dominant mutant human p53 and human MDM-2 to functionally
substitute for E6 in colony formation in PHK. Plasmids were verified for their ability to inactivate wild-type p53 by testing
their capacity to abrogate the p53 transactivation function. The results obtained showed that vectors encoding human
MDM-2 and mutant p53, while active in inhibition of p53-dependent transactivation and capable of expressing stable proteins
in PHK, failed to induce colonies of proliferating cells resistant to serum and calcium differentiation. These data argue that
p53 inactivation may not be the sole E6 function required for altering the response of PHK to serum- and calcium-triggered
differentiation. q 1997 Academic Press
INTRODUCTION to p53, thereby interfering with p53/DNA binding and
consequently with p53 transcriptional activation (Lechner
Development of anogenital cancer is strongly associ- and Laimins, 1994; Thomas et al., 1995). The second
ated with the infection by specific types of human papillo- method involves E6-mediated targeting of p53 for degra-
maviruses (HPVs) referred to as ‘‘high risk’’ or oncogenic dation through the ubiquitin system (Scheffner et al.,
(e.g., HPV16 and HPV18) (Zur Hausen, 1989). The mecha- 1990). The latter activity requires the participation of a
nisms by which HPVs contribute to the development of cellular protein, E6-associated protein (E6 AP) (Huibreg-
cancer are not fully understood. Two oncoproteins are tse et al., 1991, 1993), which acts together with E6 as a
encoded by oncogenic HPVs E6 and E7. The ability of ubiquitin ligase in the ubiquitination of p53 (Scheffner et
these viral proteins to form complexes with cellular regu- al., 1993).
latory proteins and inactivate their function has been Squamous epithelial cells are the natural host cells
suggested as a mechanism by which HPVs interfere with for HPV infection and in vitro cultured genital human
the control of cell growth and proliferation. E7 binds and
keratinocytes have been used to study the conse-
functionally inactivates members of the retinoblastoma
quences of HPV E6 and E7 expression. These studies
protein (Rb) family (Dyson et al., 1989; Davies et al., 1993).
showed that the E6 and E7 proteins cooperate to immor-
E7 binds preferentially to under-phosphorylated pRb and
talize primary human keratinocytes (PHK) (Schlegel et al.,
disrupts complexes between pRb and the E2F transcrip-
1988; Hawley-Nelson et al., 1989), alter the differentiated
tion factors (Challappen et al., 1992). E6 proteins of
phenotype of keratinocytes (Hudson et al., 1990; Halbert
HPV16 and HPV18 form complexes with p53 (Werness
et al., 1992; Woodworth et al., 1992), and inhibit keratino-et al., 1990). Two mechanisms for E6 inactivation of p53
cyte terminal differentiation induced by serum and cal-have been described. One method involves E6 binding
cium (Schlegel et al., 1988; Munger et al., 1989).
Using a quantitative keratinocyte colony formation
assay, we have recently shown that the HPV16 E6 protein1 To whom correspondence and reprint requests should be ad-
dressed. by itself, but not E7 protein, is capable of inhibiting the
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response of PHK to serum and calcium differentiation. we evaluated the ability of a dominant-negative human
mutant p53 and human MDM-2 to functionally replaceDifferentiation resistance induced by E6 protein was
found to be separable from cellular immortalization which E6 in the induction of colonies resistant to differentiation
in primary human keratinocytes.required the combined presence of E7 protein. Both wild-
type and epitope-tagged E6 proteins were active in alter- Our current study has defined amino acids 132–141
as being essential for both E6-mediated p53 degradationing keratinocyte differentiation and inducing keratinocyte
immortalization in conjunction with E7 (Sherman and and abrogation of p53 transactivation. In addition, this
study shows a correlation between the ability of E6 mu-Schlegel, 1996). The E6 protein of HPV16 is a nuclear
protein composed of 151 amino acids, many of which tant proteins to inhibit keratinocyte terminal differentia-
tion and to inactivate p53. However, the constructs en-are positively charged (Kanda et al., 1991; Lechner et al.,
1992). It contains four metal binding motifs (Cys-X-X-Cys) coding human p53 mutant and MDM-2, although verified
for being capable of expressing stable proteins in humanwith the potential to form two large zinc finger structures
(Barbosa et al., 1989). By further analysis of E6 splice keratinocytes and abrogating p53 transactivation in vivo,
failed to substitute for E6 in the colony formation assay,variants (E6I–E6IV) and a series of E6 C-terminal trunca-
tion mutants, we demonstrated that the domain between suggesting that p53 inactivation may not be the sole
requirement for inhibition of PHK terminal differentiation.amino acid residues 132 and 141, at the base of the
second putative zinc finger, is essential both for the in-
duction of differentiation resistance and for immortaliza-
MATERIALS AND METHODS
tion of PHK. Distinct domains between amino acids 120
and 151 were mapped as necessary for E6 nuclear local- Plasmids
ization (Sherman and Schlegel, 1996).
The molecular events underlying E6 and E7 biological Construction of expression plasmids encoding HPV16
E6 and E7 proteins, epitope-tagged E6 protein, and E6activities in squamous epithelial cells are not known.
Several observations and experimental data suggest that carboxy terminal deletion mutants was previously de-
scribed (Sherman and Schlegel, 1996). Schematic pre-p53 inactivation is important in the E6-dependent immor-
talization of primary human keratinocytes. HPV-immortal- sentation of the AU1-tagged full-length E6 and E6-trun-
cated mutants is shown in Fig. 1. Plasmids expressingized epithelial cells generally exhibit reduced p53 levels
and three- to fivefold reduction in the half-life of p53 as natural variants of HPV16 E6 which contain amino acid
substitutions at the N-terminal domain were recently de-compared to normal keratinocytes (Lechner et al., 1992;
Hubbert et al., 1992; Band et al., 1993). Transduction of scribed (Conrad Sto¨ppler et al., 1996). The variable amino
acids and their positions are shown in Table 1. In allhuman mutant p53 together with HPV16 E7 into PHK
caused their immortalization, suggesting that inactivation these plasmids the viral proteins are expressed from
the early SV40 promoter. Plasmids pC53-SN3 and pC53-of p53 might be the only function of E6 required for im-
mortalization of epidermal keratinocytes in conjunction SCX3, which express the human wild-type and mutant
p53, respectively, from the CMV promoter (Baker et al.,with E7 (Sedman et al., 1992). Similarly, mutant p53 can
substitute for E6 in immortalization of primary human 1990), and pCMV-MDM2 (Oliner et al., 1992) have been
described previously. Plasmids p53(s) and p53(as) weremammary epithelial cells (MEC) (Gao et al., 1996), which
require a single oncogene for immortalization. Recent obtained by recloning the p53 cDNA insert excised from
pC53-SN3 into the BamHI site of pJS55 in the sense(s)mutational analyses of the HPV16 E6 protein indicated
a strong correlation between the ability of E6 mutants to and antisense orientation with respect to the early SV40
promoter. The plasmid pG13 CAT containing the wild-induce degradation of p53 and their ability to immortalize
mammary epithelial cells (Dalal et al., 1996) or embryonic type p53 binding site upstream of the polyomavirus early
promoter and the CAT gene was previously describedkidney cells in conjunction with E7 (Nakagawa et al.,
1996). In the latter cells, however, degradation of p53 (Kern et al., 1992).
appears not to be the only E6-mediated function required
for immortalization. To date there have been no muta- Cell cultures and transfections
tional studies correlating the ability of E6 protein to abro-
gate keratinocyte terminal differentiation and to inacti- Saos-2 cells were grown in Dulbecco’s modified Eagle
medium (DMEM) supplemented with 10% fetal calf serumvate p53.
To address whether HPV16 E6’s ability to inhibit kera- (FCS). For transfection, cells were plated into 6- or 9-cm
dishes and transfected by a modified calcium phosphatetinocyte terminal differentiation depends on p53 inactiva-
tion, we analyzed a panel of E6 carboxy terminal trunca- method as previously described (Sherman and Schlegel,
1996). Primary human keratinocytes (PHK) cultured fromtion mutants and E6 natural variants, previously defined
for their inhibitory activities in keratinocyte differentiation, neonatal foreskin explants were grown in keratinocyte-
SFM (K-SFM) supplemented with 5 ng/ml epidermalfor their abilities to target p53 for degradation in vitro,
and to abrogate p53 transactivation in vivo. In addition, growth factor (EGF) and 50 mg/ml bovine pituitary extract
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(BPE) (Gibco-BRL, Gaithersburg, MD). Keratinocytes ried out at 377 for 60 min in 12.5 ml of reaction mixture
containing the cRNA template, 8.8 ml of RTL extract, 0.25were transfected at passage two using Lipofectin (BRL).
ml of amino acid mixture minus methionine (1 mM each
Induction of colonies resistant to serum/Ca2/ amino acid), 28 mCi of labeling mix containing 30% [35S]-
differentiation in PHK cysteine, and 70% [35S]methionine (1000 Ci/mM) (PRO-
MIX, Amersham), and 12.5 U RNasin. In vitro translationAssays for the induction of colonies resistant to differ-
of E6 and the mutant proteins in wheat germ extractentiation were carried out as described previously
(WGE) (Promega) was carried out at 257 for 60 min in 25(Schlegel et al., 1988). Briefly, cells were plated at 50%
ml of reaction mixture containing the cRNA template, 13confluency in 10-cm dishes and transfected (lipofected)
ml of WGE extract, 2 ml of amino acid mixture minuswith 10 mg of the E6 test plasmid together with 10 mg of
cysteine (1 mM each amino acid), 28 mCi of the labelingthe E7 expression plasmid (pE7) or 10 mg of the vector
mixture, and 12.5 U of RNasin.DNA. The second day after transfection, cells were plated
into 162-cm2 flasks in K-SFM and maintained until the
p53 degradation assayscultures became confluent (4–5 days). The medium was
then changed to a selection medium consisting of DMEM Assays for E6-directed, ubiquitin-dependent degrada-
(containing 2 mM calcium) supplemented with 10% FCS tion of p53 were carried out as previously described
and 1 mg/ml hydrocortisone (Sigma). Cultures were main- (Scheffner et al., 1990; Crook et al., 1991). Briefly, 12.5 ml
tained in selection medium for 2–3 weeks to allow the of in vitro-translated p53 in RTL and 25 ml of E6 protein
formation of serum/Ca2/-resistant colonies. translated in WGE were mixed in a total volume of 45 ml
of reaction mixture containing 2.5 ml additional RTL, 25
Western blot analysis mM Tris–HCl (pH 7.5), 100 mM NaCl, and 3 mM DTT.
After removal of an aliquot for the zero time point theCells from 9-cm dishes were lysed in modified RIPA
reaction was incubated at 257. At various time pointsbuffer (20 mM MOPS, 150 mM NaC1, 1 mM EDTA, 1% NP-
aliquots were removed and mixed with equal volume of40, 1% deoxycholate, and 0.1% SDS) containing protease
21 SDS–PAGE sample buffer. Samples were resolvedinhibitors (0.1 mM TLCK, 0.1 mM TPCK, and 0.5 mM
on SDS–12.5% PAGE. Gels were exposed to X-ray filmsPMSF). The protein concentration in the lysate was deter-
for 6–48 hr. For quantification of p53 degradation, autora-mined with the Bio-Rad protein Assay and 100 mg from
diographs were densitometrically scanned (CAMAG, TLCeach lysate was electrophoresed on a 10% polyacryl-
Scanner II).amide–SDS gel. Proteins were transferred onto nitrocel-
lulose paper using a semi-dry blotter. Filters were cut
p53 transactivation assaysinto strips and reacted with specific antibodies. MDM-2
was detected with a monoclonal antibody against human Saos-2 cells (8 1 105) were plated into 6-cm dishes.
MDM-2 (a gift from M. Oren). p53 was detected with the The following day duplicate cultures were transfected
monoclonal antibody DO-1 (Santa Cruz Biotechnology with 1 mg of pG13 CAT, 3 mg of p53 expression plasmid,
Inc.) The human superoxide dismutase (SOD-1) protein and 5–20 mg of the E6 expression plasmid or vector
was detected with rabbit polyclonal antibodies (a gift DNA. Cells were harvested 48 hr later and CAT activity
from Y. Groner). Following incubation with the first anti- was assayed by the method of Gorman et al. (1982) as
body, membranes were reacted with goat antimouse an- previously described (Sherman et al., 1989). Percentage
tibody conjugated to horseradish peroxidase (Jackson of chloramphenicol acetylation was quantified by scan-
Laboratories) (for monoclonal antibodies) or protein A ning the silica gel sheet on a Bio-Rad PhosphorImager.
peroxidase (Amersham) (for rabbit polyclonal antibodies) CAT activity was normalized for the amount of protein.
followed by enhanced chemiluninescence detection To confirm efficient transfection of DNA, transfections
(ECL, Amersham) according to the manufacturer’s in- were carried out with 1 mg DNA of CMV–b-galactosidase
structions. plasmid and b-gal activity was determined using O-ni-
trophenyl b-D-galactopyranoside as a colorimetric sub-
In vitro transcription/translation strate.
RNA of p53 was transcribed from the human p53 cDNA
RESULTScloned into pGEM (Promega). The AU1-tagged E6 and
deletion mutant cRNAs were transcribed from the JS55 Activity of E6 protein truncation mutants in targeting
plasmids described above. All cRNAs were synthesized p53 for degradation
from 1 mg linearized template DNA with T7 RNA polymer-
ase using the mCAP mRNA capping kit (Stratagene). Inactivation of p53 has been suggested as a mecha-
nism by which HPVs contribute to epithelial carcinogene-Eight to 16% of the cRNA product was used for in vitro
translation. In vitro translation of p53 in nuclease-treated sis. One mechanism may be the ability of high risk HPV
E6 proteins to induce the degradation of p53.rabbit reticulocyte cell lysate (RTL) (Promega) was car-
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FIG. 1. Schematic representation of HPV16 E6 and C-terminal truncated mutants tagged with the AU1 epitope A1 (suffix ‘‘A’’) at the C-terminus.
The construction of the indicated plasmids has been previously described (Sherman and Schlegel, 1996) and the mutants were named according
to the numbers of the last amino acid residue present in the E6 truncated ORF. These mutants have been numbered M11–M15 for simplification.
We have recently shown that HPV16 E6 is capable of ing 10 amino acids from the carboxyl end of E6 was
active in this assay almost to the same extent as full-inducing colonies of proliferating cells resistant to se-
rum/Ca2/ differentiation in primary human keratinocytes length E6 (Figs. 3A and 3B). Mutant 132 from which an
additional 9 amino acids were eliminated (as well as(Sherman and Schlegel, 1996). Functional analysis of E6
carboxy terminal deletion mutants tagged with the epi- mutants containing larger deletions upstream of residue
132) were completely defective in their capacity to targettope AU1 (shown in Fig. 1). pointed to the necessity of
the domain spanning residues 141–132 for E6 biological p53 for degradation. This altered biochemical activity cor-
related with impaired E6 biological activity.activity. To address whether E6’s ability to alter keratino-
cyte differentiation was associated with its ability to tar-
get p53 for degradation, we assessed the capacity of Activity of E6 protein truncation mutants in
the mutants described above to induce p53 degradation. abrogation of p53 transactivation
Induction of p53 degradation was tested in vitro using in
vitro synthesized 35S-radiolabeled p53 and E6 proteins. The physical association of E6 proteins of the ‘‘high
risk’’ HPV types (HPV16 and HPV18) with p53 preventsp53 protein translated in reticulocyte lysates and E6 pro-
tein translated in wheat germ extracts were mixed in a p53 binding to DNA and results in abrogation of p53
transcriptional modulatory functions (Lechner et al., 1992;standard reaction and incubated at 257. Levels of p53
remaining in the reaction at different time points were Crook et al., 1994; Thomas et al., 1995). In some studies,
E6 inhibition of p53 transactivation was shown to bedetermined by SDS–PAGE analysis (Fig. 2A) and the
relative amount of E6 protein present in the extracts is separable from the ability of E6 to target p53 for degrada-
tion (Crook et al., 1994; Pim et al., 1994). To further investi-indicated in Fig. 2B. The extent of p53 degradation was
quantified by densitometric scanning of the p53 bands gate the correlation between E6 biological activity in dif-
ferentiation inhibition and E6 biochemical activities af-in the autoradiograph. Figure 3A shows data of a repre-
sentative assay. Average degradation activities of the fecting p53, we tested the activity of the epitope-tagged
E6-truncated mutants in inhibition of p53 transactivation.various E6 proteins obtained from three independent
assays are shown in Fig. 3B. The p53 deficient Saos-2 cells were transfected with 1
mg of the p53 reporter plasmid pG13CAT (Kern et al.,Full-length E6 protein tagged with the AU1 epitope
was capable of inducing degradation of p53 in vitro, indi- 1992), 3 mg of p53 expression plasmid, and 10 mg of E6
encoding plasmid or vector plasmid pJS55. CAT activitycating that fusion of the epitope to the carboxyl end of
E6 did not interfere with its biochemical activity. Activity was assayed in cell extracts prepared 48 hr after trans-
fection. Transfection of p53 strongly transactivated CATof the epitope-tagged E6 protein was comparable to that
of wild-type E6 (data not shown). Mutant141 (M11) lack- expression from the reporter pG13CAT and this p53-de-
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FIG. 2. (A) In vitro p53 degradation assay with E6 and E6 truncated proteins. 35S-labeled p53 and E6 proteins synthesized in RTL and WGE,
respectively, were mixed in a standard reaction and incubated at 257. Samples were removed at time 0, 20 min, 1 hr, and 3 hr and analyzed by
SDS–PAGE and autoradiography. (B) Relative amounts of synthesized E6 proteins. Ten percent of the E6 translation products from (A) were analyzed
by SDS–PAGE and autoradiography.
pendent transactivation was inhibited by cotransfection et al., 1996). One variant surpassed the reference E6
of E6 (Fig. 4). Plasmids encoding wild-type or epitope- protein in its ability to abrogate keratinocyte differentia-
tagged E6 proteins were active in abrogation of p53- tion responses, whereas another showed a reduction in
mediated transactivation. The extent of inhibition corre- this activity. The biological activities of the E6 proteins
lated with the amount of transfected E6 DNA (data not were directly correlated with their abilities to induce p53
shown). Cotransfection of mutant 141 (M11) greatly inhib- degradation in vitro. Four (including reference) of these
ited p53 transactivation (Fig. 5A), similar to the inhibition natural variants of HPV16 E6 (Table 1), previously defined
observed with full-length E6. Mutant 132 (M12) and mu- for their abilities to alter keratinocyte differentiation and
tants carrying larger deletions (M13–M15) lacked com- to induce p53 degradation, were assessed for their ca-
pletely the ability to suppress p53-dependent transactiva- pacity to abrogate p53 transactivation.
tion. These experiments were repeated three times and The extent of inhibition exhibited by the full-length E6
the average results ({ standard deviation) are shown in reference protein (wild-type E6) was comparable to that
Fig. 5B. These data indicated the necessity of the region of the AU1-tagged E6 protein tested in the same experi-
between residues 132 and 141 for the E6-mediated inhi- ments (Fig. 6). All three variants were active in abrogation
bition of p53 transactivation. of p53 transactivation and showed stronger inhibitory
activity than the reference E6. The variant 512 showed
the strongest inhibition. This variant also showed theE6 natural variants dissociate biological activity and
strongest p53 degradation activity and biological activityp53 degradation from abrogation of p53
in PHK (Conrad Sto¨ppler et al., 1996). However, the abilitytransactivation
of the other E6 variants to degrade p53 (Conrad Sto¨pplerNatural variants of HPV16 E6 carrying amino acid sub-
et al., 1996) did not correlate with their ability to inhibitstitutions near the N-terminus were recently reported to
p53 transactivation. For example, E6 reference and vari-differ in their abilities to abrogate keratinocyte differentia-
tion in response to serum and calcium (Conrad Sto¨ppler ant 162 proteins showed comparable activities in p53
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FIG. 3. (A) Rate of p53 degradation induced by HPV16 E6 and E6 truncation mutants. Assays were carried out as described in the legend to Fig.
2. The levels of p53 at various time points were quantified by densitometric scanning and presented as percentage of the input p53 (time 0). Data
from a representative assay are shown. (B) Average values for degradation of p53 after 3 hr of incubation. Three independent assays were carried
out under standard conditions (with E6 and p53 obtained from translation of 8% of the respective cRNA products). Increasing the amount of input
E6 protein in the degradation reactions up to fourfold (translation of 34% of the cRNA product) did not change the activities of mutants M12–M15
in p53 degradation (data not shown). The mean values for p53 remaining after 3 hr incubation (p53 degradation) are shown with standard deviation.
degradation but variant 162 was more active than the DNA of plasmids encoding the p53 mutant described
above (p53M) (Baker et al., 1990), and human MDM-2reference E6 in inhibition of p53-dependent transactiva-
tion. More importantly, variant 84, which showed the low- (an inhibitor of p53 (Momand et al., 1992), were trans-
fected into PHK alone and in combination with E7. Theest activity in p53 degradation, and abrogation of kera-
tinocyte differentiation (Conrad Sto¨ppler et al., 1996) ex- plasmid encoding the epitope-tagged E6 protein (E6A)
was transfected as a positive control. Transfected cellshibited stronger inhibition of p53 transactivation than the
E6 reference and variant 162. were selected in differentiation selection medium to
allow the formation of serum/Ca2/-resistant colonies.
After 3 weeks of selection, colonies were observed inHuman MDM-2 and human dominant-negative mutant
the E6A-transfected cultures. As expected E6-inducedp53 do not substitute for E6 in the human
keratinocyte assay
Results of the experiments described above pointed
to the necessity of the domain spanning amino acid resi-
dues 132–141 for the ability of E6 to suppress p53 trans-
activation and induce its degradation. This domain of
HPV16 E6 was also identified as crucial for the induction
of differentiation resistance, suggesting a correlation be-
tween p53 inactivation and induction of differentiation
resistance.
In previous studies it was demonstrated that a domi-
nant negative mutant of p53 with a substitution of alanine
for valine at residue 143 can cooperate with HPV16 E7
to immortalize primary human keratinocytes, suggesting
that p53 inactivation might be the sole function of E6 in
FIG. 4. Autoradiograph of CAT assay showing abrogation of p53-immortalization (Sedman et al., 1992). To test whether
mediated transactivation by wild-type and AU1-tagged E6 proteins.p53 inactivation mediates E6-induced resistance to dif-
Saos-2 cells were transfected with 1 mg of pG13CAT, 3 mg of p53
ferentiation stimuli, we examined the ability of vectors expression plasmid, 10 mg of E6 plasmid or vector DNA as indicated,
encoding p53 inhibitory proteins to functionally replace and 1 mg of pCMV-b gal. CAT activity was determined 48 hr post-
transfection.E6 in the keratinocyte colony assay (Fig. 7 and Table 2).
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FIG. 5. Abrogation of p53-mediated transactivation by wt E6 and truncated proteins. Saos-2 cells were transfected as described in the legend to
Fig. 4. CAT activity was determined in cell extracts prepared 48 hr posttransfection. (A) Autoradiograph of a representative assay. (B) The percentage
of chloramphenicol acetylation was quantified with a phosphorImager (Bio-Rad) and presented as percentage of the control extract activity (cells
transfected with pJS55). Relative activity values from three independent experiments with standard deviations are shown.
keratinocyte colonies with altered differentiation. How- 8B). Transfection of 10 mg DNA of plasmids expressing
human mutant p53 and MDM-2 inhibited the transactiva-ever, all other tested DNAs failed to induce colonies ei-
ther when transfected alone or in combination with the tion activity of the cotransfected wild-type p53. A con-
struct encoding anti-sense p53 RNA (included in theseplasmid encoding HPV16 E7 (Fig. 7 and Table 2).
Since the lack of activity of the above vectors in the assays) showed no inhibitory activity. Additional experi-
ments carried out with equivalent molar quantities of thecolony assay could result from an inability of the vectors
used to inactivate the wild-type p53 function or inability plasmid DNAs, including E6A, indicated that the inhibi-
to express stable proteins in human keratinocytes, the
following control experiments were performed. To verify
the activity of the constructs used in the keratinocyte
assay we tested their capacity to abrogate p53-depen-
dent transcription activation in Saos-2 cells (Figs. 8A and
TABLE 1
Variable Amino Acids in Natural HPV-16 Variantsa
Amino acid in sequence of:
Variant
Position Reference 512 162 z84
E6
10 R — G I
14 Q H D D
64 D — E —
78 H Y Y Y FIG. 6. Abrogation of p53-mediated transactivation by natural E6
variants. Saos-2 cells were transfected with 1 mg DNA of pG13 CAT,83 L V V —
138 S C — — 3 mg of p53 expression plasmid, and 10 mg DNA of pJS55 or plasmids
encoding E6 variants pMSI.Z84 (v84), pMSI.162 (v162), pMSI.512 (v512),E7
29 N — — S or pMSI ref (E6 ref) reference full-length E6 (Conrad Sto¨ppler et al.,
1996). Average values of relative CAT activities (percentage of the
control extract activity) obtained from two independent assays area Cloning of the indicated variant DNAs was previously reported
(Conrad Sto¨ppler et al., 1996). shown.
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FIG. 7. Keratinocyte colony formation assay. Plasmids encoding HPV-16 E6, human MDM-2, and human mutant p53 were evaluated for their
ability to induce altered keratinocyte differentiation in serum/Ca2/. Human keratinocytes were transfected with 14 mg DNA of plasmids encoding
human MDM-2 or mutant p53 and 10 mg DNA of plasmids encoding epitope-tagged HPV16 E6 (E6A) or vector alone. Selection in DMEM containing
10% serum and 1 mg/ml hydrocortisone was carried out for 3 weeks. Flasks were stained with methylene blue to visualize colonies.
tory activities of MDM-2 and of the mutant p53 were DISCUSSION
comparable to that of E6A (Fig. 8B).
In this study vectors expressing epitope-tagged HPV16In the vectors used in this study, expression of MDM-
E6 and E6 truncation mutants were used to study their2 and p53M is from the CMV promoter, while E6A is
interactions with p53 and correlated with their previouslyexpressed from the early SV40 promoter. To rule out the
defined ability to inhibit keratinocyte terminal differentia-possibility that inactivity of the mutant p53 and MDM-2
tion. All vectors were verified for their ability to expressin the colony induction assay was the result of failure to
stable proteins either when translated in vitro in WGE orexpress stable proteins in human keratinocytes, expres-
in vivo in COS cells. The ability of the proteins to bind tosion of these proteins in transfected keratinocytes was
p53 was evaluated by testing their capacity to suppressevaluated by Western blot analysis (Fig. 9). These analy-
the p53-mediated transcriptional activation function. In-ses indicated that both MDM-2 and mutant p53 proteins
duction of p53 degradation was assayed in vitro by moni-were expressed at high levels in human keratinocytes.
toring the levels of p53 in reaction mixtures of in vitro-MDM-2 protein was detected only in cells transfected
synthesized E6 and p53 proteins. Full-length E6 protein,with the respective vector DNA. Much higher levels of
tagged with the epitope AU1, displayed high activity inp53 were detected in cells transfected with the mutant
the abrogation of p53 transactivation and targeting of p53p53 as compared to cells transfected with the vector
for degradation. Deletion of the region spanning aminoplasmid or MDM-2 plasmid. This probably reflects both
acids 142–151 (at the carboxy terminus of E6 and paststrong transcription of p53 RNA from the CMV promoter
the second putative zinc finger) did not impair any ofas well as longer half-life of the mutant p53 protein com-
these tested functions. Activity of mutant 141 (M11) waspared to the wild-type endogenous p53.
comparable to that of full-length E6 both biologically
(Sherman and Schlegel, 1996) and biochemically, indicat-
ing that this region is dispensable for mediating p53TABLE 2
degradation, abrogation of p53 transactivation, and in-
Activities of Human MDM-2 and Mutant p53 in the Induction of duction of resistance to differentiation. Our data are
Serum and Ca2/-Resistant Colonies in Human Keratinocytes
somewhat different from a previous mutational analysis
which demonstrated reduced activity of mutants carryingExperiment 1 Experiment 2
Plasmida No. of colonies No. of colonies small deletions within the region spanning amino acids
140–151, both in p53 binding and degradation (Foster et
E6A 22 16 al., 1994). This could result from differences in the stabil-
E6A / E7 27 19
ity of the proteins or the assays used for evaluation ofMDM-2 0 0
p53 binding. We show that further deletion of the regionMDM-2 / E7 0 0
p53M 0 0 spanning amino acids 132 through 141 completely abol-
p53M / E7 0 0 ished E6 capacity to target p53 for degradation and in-
Vector 0 0 hibit p53 transactivation. The same domain was also
mapped by us as essential for the capacity of E6 to altera Transfections were carried out with equimolar quantities of the
keratinocyte differentiation in response to serum and cal-indicated plasmids (10 mg DNA of pE6A, pE7, and JS55. 14 mg DNA of
plasmids encoding human p53M and MDM-2). cium, thus suggesting a possible association between
AID VY 8778 / 6a4f$$$143 10-01-97 10:51:15 vira AP: VY
304 SHERMAN ET AL.
FIG. 8. Abrogation of p53-mediated transactivation by plasmids encoding human mutant p53 and human MDM-2. Transfections into Saos-2 cells
were carried out as described in the legend to Fig. 4. (A) Autoradiograph of a representative assay in which 10 mg DNA of the indicated plasmids
were transfected. (B) Average values of CAT relative activities from three independent experiments with standard deviations. In these assays 14
mg DNA of the indicated plasmids was transfected except for pE6A which was transfected at 10 mg.
p53 inactivation and induction of resistance to differen- the importance of the finger structure for p53 binding and
degradation activity as well as inhibition of keratinocytetiation.
Mutant 132 (M12) contains most of the amino acid differentiation. Elimination of the carboxyl end of the sec-
ond cysteine finger could result in unproper folding ofsequences constituting the second putative zinc-finger
except from the last cysteine motif (133–136), which is the resulting protein or its decreased stability, although
evidence from expression studies in COS cells seem tonecessary for formation of the finger structure. Loss of
all the tested functions by mutant 132 strongly supports contradict the latter possibility. Expression levels of
M132 (M12) detected in COS cells were comparable to
those of M141 (M11) as indicated by immunoprecipita-
tion and fluorescence staining analyses. Moreover, M132
retained partial ability to translocate to the nucleus (Sher-
man and Schlegel, 1996). Our data are compatible with
previous mutational analyses of HPV16 E6 (Foster et al.,
1994; Dalal et al., 1996), showing that point mutations in
amino acid residues located within the second finger
domain, including the last cysteine residue at 136, or
small deletions upstream of residue 132, caused com-
plete loss of E6 ability to bind p53 and induce its degra-
dation both in vitro and in vivo. In other studies, however,
disruption of the carboxyl base of the second finger by
deletion of amino acids 133 through 137 only partially
FIG. 9. Western blot analysis of human keratinocytes transfected reduced E6 ability to bind p53 and cause its degradation
with human mutant p53 and human MDM-2. Human keratinocytes were (Crook et al., 1991, 1994).
transfected with 14 mg DNA of the indicated plasmids, grown to conflu-
Previous analyses of HPV16 E6 suggest that p53 deg-ency in KSFM, and then switched to differentiation medium and further
radation and binding functions may be encoded by dis-incubated for 3 days. Lysates were prepared in RIPA buffer and 100-
mg protein aliquots were subjected to Western blot analysis using the tinct DNA sequences (Crook et al., 1991; Thomas et al.,
indicated antibody. Expression of MDM-2 was detected only in cells 1995). With the truncation mutants that we generated,
transfected with the respective plasmid. p53 was detected in all trans- we were unable to separate between these functions or
fected cells but in much higher levels in cells transfected with mutant
identify separate sequences required for altering PHKp53 (p53 M). The level of expression of superoxide dismutase (SOD)
differentiation.was equivalent in cell samples, indicating equal protein loading in
these gels. However, analysis of the natural E6 variants did sug-
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gest dissociation of the E6-mediated abrogation of p53 mutants we were unable to separate between the immor-
talizing and differentiation inhibitory activities of E6 (Sher-transactivation from the E6-induced p53 degradation and
inhibition of keratinocyte differentiation. The E6 variant man and Schlegel, 1996). Neither could we separate be-
tween the biological activities of E6 and its ability toZ84 (V84), even though less active than the reference E6
and the other tested variants in p53 degradation and inactivate p53 (p53 degradation and abrogation of p53
transactivation). Study of additional mutants carryinginhibition of differentiation (Conrad Sto¨ppler et al., 1996),
exhibited higher inhibitory activity than the reference E6 small deletions and point mutations may possibly enable
dissociation between these functions.in p53-mediated transactivation. Yet, these data could
also result from differences in the levels of expression
of the E6 protein between Saos-2 cells and PHK. Since ACKNOWLEDGMENTS
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We thank B. Vogelstein, J. Schiller, M. Oren, and Y. Groner for dona-study, the possibility exists that the higher inhibitory ac-
tion of plasmids and antibodies. This work was supported in part bytivity of V84 was due to the high level of protein expres-
the Recanati Foundation for Medical Research, Tel-Aviv University, andsion in the transiently transfected Saos-2 cells.
by the Cooperation Program in Cancer Research of the Deutsches
Our data demonstrating the failure of a dominant nega- Krebsforschungzentrum (DKFZ) and Israel’s Ministry of Science and
tive mutant human p53 and human MDM-2 to functionally the Arts Project No. 01499 awarded to L.S.
replace E6 in the colony formation assay suggest that
p53 inactivation may not be the sole requirement for
REFERENCESthe induction of resistance to differentiation stimuli. For
example, resistance to serum and calcium could be me- Baker, S. J., Markowitz, S., Fearon, E. R., Willson, J. K. V., and Vogelstein,
B. (1990). Suppression of human colorectal carcinoma cell linediated through the interaction of E6 with other cellular
growth by wild type p53. Science 249, 1912–1915.proteins. Apart from p53 and the 100-kDa E6-associated
Band, V., Dalal, S., Delmolino, L., and Androphy, E. J. (1993). Enhancedprotein (E6 AP), specific association of E6 with several
degradation of p53 protein in HPV-6 and BPV-1 E6 immortalized
cellular proteins has been reported (Keen et al., 1994), human mammary epithelial cells. EMBO J. 12, 1847–1852.
including the recently identified E6 binding protein Barbosa, M. S., Lowy, D. R., and Schiller, J. T. (1989). Papillomavirus
polypeptides E6 and E7 are zinc-binding proteins. J. Virol. 63, 1404–(E6BP), which is identical to the putative calcium binding
1407.protein, ERC-55 (Chen et al., 1995). An alternative expla-
Chellapan, S., Kraus, V., Kroger, B., Munger, K., Howley, P. M., Phelps,nation for the results obtained may be that MDM-2 and
W. C., and Nevins, J. R. (1992). Adenovirus E1A, simian virus 40 tumor
the dominant negative allele of p53 used herein, although antigen and human papillomavirus E7 proteins share the capacity
effectively disrupting the transcriptional activity of p53, to disrupt the interaction between the transcription factor E2F and
retinoblastoma gene product. Proc. Natl. Acad. Sci. USA 89, 4549–may not efficiently target a function of p53 that contri-
4553.butes to the cellular differentiation resistance phenotype.
Chen, J. J., Reid, C. E., Band, V., and Androphy, E. J. (1995). InteractionThe particular mutant of human p53 used in our study
of papillomavirus E6 oncoprotein with a putative calcium-binding
was shown by Sedman et al. (1992) to be capable of protein. Science 269, 529–531.
substituting E6 in the immortalization of PHK in coopera- Conrad Sto¨ppler, M., Ching, K., Sto¨ppler, H., Clancy, K., Schlegel, R.,
and Icenogle, J. (1996). Natural variants of human papillomavirustion with E7. Inactivation of p53 may be critical in the
type 16 E6 protein differ in their abilities to alter keratinocyte differen-immortalization of PHK, as indicated by the ability of the
tiation and to induce p53 degradation. J. Virol. 70, 6987–6993.dominant mutant p53 to substitute for E6. It is, however,
Crook, T., Tidy, J. A., and Vousden, K. H. (1991). Degradation of p53 can
possible that E6 contributes to keratinocyte immortaliza- be targeted by HPV E6 sequences distinct from those required for
tion by more than one function. In the study of Sedman p53 binding and transactivation. Cell 67, 547–556.
Crook, T., Fisher, C., Masterson, P., and Vousden, K. H. (1994). Modula-et al., cells transfected by the mutant p53 plus E7 were
tion of transcriptional regulatory properties of p53 by HPV E6. Onco-selected in medium containing Geneticin (G418) and
gene 9, 1225–1230.then further passaged in serum-free keratinocyte me-
Dalal, S., Gao, Q., Androphy, E. S., and Band, V. (1996). Mutational
dium (KGM). The immortalized lines obtained do not nec- analysis of human papillomavirus type 16 E6 demonstrates that p53
essarily represent cells which have acquired resistance degradation is necessary for immortalization of mammary epithelial
cells. J. Virol. 70, 683–688.to serum- and calcium-induced differentiation. In this re-
Davies, R., Hicks, R., Crook, T., Morris, J., and Vousden, K. (1993).gard it should be mentioned that Sedman et al. pointed
Human papillomavirus type 16 E7 associates with a histone H1 ki-in their report that keratinocytes transfected by the mu-
nase and with p107 through sequences necessary for transformation.
tant p53 plus E7, although exhibiting extended life span J. Virol. 67, 2521–2528.
(more than 30 passages), grew more slowly than kera- Dyson, N., Howley, P. M., Munger, K., and Harlow, E. (1989). The human
papillomavirus 16 E7 oncoprotein is able to bind the retinoblastomatinocytes immortalized by E6 plus E7, suggesting that
gene product. Science 243, 934–937.other activities of E6 besides p53 inactivation may play
Foster, S. A., Demers, G. W., Etscheid, B. G., and Galloway, D. A. (1994).a facilitating role in promoting cell growth. Inhibition of
The ability of human papillomavirus E6 protein to target p53 for
keratinocyte terminal differentiation could be one of degradation in vivo correlates with their ability to abrogate actinomy-
these activities. cin D-induced growth arrest. J. Virol. 68, 5698–5705.
Gao, Q., Hauser, S. H., Liu, X-L., Wazer, D. E., Madoc-Jones, H., andBy testing the biological activities of the E6 truncation
AID VY 8778 / 6a4f$$$143 10-01-97 10:51:15 vira AP: VY
306 SHERMAN ET AL.
Band, V. (1996). Mutant p53-induced immortalization of primary hu- together are necessary and sufficient for transformation of primary
human keratinocytes. J. Virol. 63, 4417–4421.man mammary epithelial cells. Cancer Res. 56, 3129–3133.
Nakagawa, S., Watanabae, S., Yoshikawa, H., Taketani, Y., Yoshiike,Gorman, C. M., Moffat, L. F., and Howard, B. H. (1982). Recombinant
K., and Kanda, T. (1996). Mutational analysis of human papillomavirusgenomes which express chloramphenicolacetyl-transferase in mam-
type 16 E6 protein: Transforming function for human cells and degra-malian cells. Mol. Cell Biol. 2, 1044–1051.
dation of p53 in vitro. Virology 212, 535–542.Halbert, C. L., Demers, G. W., and Galloway, D. A. (1992). The E6 and
Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., and Vogelstein,E7 genes of human papillomavirus type 6 have weak immortalizing
B. (1992). Amplification of a gene encoding a p53 associated proteinactivity in human epithelial cells. J. Virol. 66, 2125–2134.
in human sarcomas. Nature 358, 80–83.
Hawley-Nelson, P., Vousden, K. H., Hubbert, N. L., Lowy, D. R., and Pim, D., Storey, A., Thomas, M., Massimi, P., and Banks, L. (1994).
Schiller, J. T. (1989). HPV-16 E6 and E7 proteins cooperate to immor- Mutational analysis of HPV18 E6 identifies domains required for
talize human foreskin keratinocytes. EMBO J. 8, 3905–3910. p53 degradation in vitro, abolition of p53 transactivation in vivo and
Hubbert, N. L., Sedman, S. A., and Schiller, J. T. (1992). Human papillo- immortalization of primary BMK cells. Oncogene 9, 1869–1876.
mavirus type 16 E6 increases the degradation rate of p53 in human Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., and How-
keratinocytes. J. Virol. 66, 6237–6241. ley, P. M. (1990). The E6 oncoprotein encoded by human papillomavi-
Hudson, J. B., Bedell, M. A., McCance, D. J., and Laimins, L. A. (1990). rus type 16 and 18 promotes the degradation of p53. Cell 63, 1129–
Immortalization and altered differentiation of human keratinocytes in 1136.
Scheffner, M., Huibregtse, J. M., Vierstra, R. D., and Howley, P. M.vitro by the E6 and E7 open reading frames of human papillomavirus
(1993). The HPV-16 E6 and E6-AP complex functions as a ubiquitintype 18. J. Virol. 64, 519–526.
protein ligase in the ubiquitination of p53. Cell 75, 495–505.Huibregtse, J. M., Scheffner, M., and Howley, P. M. (1991). A cellular
Schlegel, R., Phelps, W. C., Zhang, Y.-L., and Barbosa, M. (1988). Quanti-protein mediates association of p53 with E6 onocoprotein of human
tative keratinocyte assay detects two biological activities of humanpapillomavirus types 16 or 18. EMBO J. 10, 4129–4135.
papillomavirus DNA and identifies viral types associated with cervi-Huibregtse, J. M., Scheffner, M., and Howley, P. M. (1993). Cloning and
cal carcinoma. EMBO J. 7, 3181–3187.expression of the cDNA for E6-AP, a protein that mediates the inter-
Sedman, S. A., Hubbert, N. L., Vass, W. C., Lowy, D. R., and Schiller,action of the human papillomavirus E6 oncoprotein with p53. Mol.
J. T. (1992). Mutant p53 can substitute for human papillomavirus typeCell. Biol. 13, 775–784.
16 E6 in immortalization of human keratinocytes but does not have
Kanda, T., Watanabe, S., Zanma, S., Sato, H., Furuno, A., and Yoshiike, E6-associated transactivation or transforming activity. J. Virol. 66,
K. (1991). Human papillomavirus type 16 E6 protein with glycine 4201–4208.
substitution for cysteine in the metal-binding motif. Virology 185, Sherman, L., and Schlegel, R. (1996). Serum and calcium induced differ-
536–548. entiation of human keratinocytes is inhibited by the E6 oncoprotein
Keen, N., Elston, R., and Crawford, L. (1994). Interaction of the E6 protein of human papillomavirus type 16. J. Virol. 70, 3269–3279.
of human papillomavirus with cellular proteins. Oncogene 9, 1493– Sherman, L., Yaniv, A., Lichtman-Pleban, H., Tronick, S. R., and Gazit,
1499. A. (1989). Analysis of regulatory elements of the equine infectious
anemia virus and caprine arthritis-encephalitis virus long terminalKern, S. E., Pietenpol, J. A., Thiagalingam, S., Seymour, A., Kinzler, K. W.,
repeat. J. Virol. 63, 4925–4931.and Vogelstein, B. (1992). Science 256, 827–830.
Thomas, M., Massimi, P., Jenkins, J., and Banks, L. (1995). HPV18 E6Lechner, M. S., Mack, D. H., Finicle, A. B., Crook, T., Vousden, K. H.,
mediated inhibition of p53 DNA binding activity is independent of E6and Laimins, L. A. (1992). Human papillomavirus E6 proteins bind
induced degradation. Oncogene 10, 261–268.p53 in vivo and abrogate p53 mediated repression of transactivation.
Werness, B. A., Levine, A. J., and Howley, P. M. (1990). Association ofEMBO J. 11, 3045–3052.
human papillomavirus types 16 and 18 E6 proteins with p53. Science
Lechner, M. S., and Laimins, L. A. (1994). Inhibition of p53 DNA binding
248, 76–79.
by human papillomavirus E6 protein. J. Virol. 68, 4262–4273. Woodworth, C. D., Cheng, S., Simpson, S., Hamacher, L., Chow, L. T.,
Momand, J., Zambetti, G. P., Olson, D. C., George, D., and Levine, A. J. Broker, T. R., and Dipaolo, J. A. (1992). Recombinant retroviruses en-
(1992). The mdm-2 oncogene product forms a complex with the p53 coding human papillomavirus type 18 E6 and E7 genes stimulate
protein and inhibits p53 mediated transactivation. Cell 69, 1237– proliferation and delay differentiation of human keratinocytes early
1245. after infection. Oncogene 7, 619–626.
Munger, K., Phelps, W. C., Bubb, V., Howley, P. M., and Schlegel, R. Zur Hausen, H. (1989). Papillomaviruses as carcinomaviruses. Adv.
Viral Oncol. 8, 1–26.(1989). The E6 and E7 genes of the human papillomavirus type 16
AID VY 8778 / 6a4f$$$144 10-01-97 10:51:15 vira AP: VY
